A5042482253- Vasculitis and related conditions
- IgG4-Related and Inflammatory Diseases
- Neuroendocrine Tumor Research Advances
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Otitis Media and Relapsing Polychondritis
- Gastrointestinal disorders and treatments
- Systemic Lupus Erythematosus Research
- Urticaria and Related Conditions
- Renal Diseases and Glomerulopathies
- Sarcoidosis and Beryllium Toxicity Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Autoimmune Bullous Skin Diseases
- Systemic Sclerosis and Related Diseases
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Pancreatitis Pathology and Treatment
- Soft tissue tumor case studies
- Cell Adhesion Molecules Research
- Platelet Disorders and Treatments
- Rheumatoid Arthritis Research and Therapies
- Eosinophilic Disorders and Syndromes
- Atherosclerosis and Cardiovascular Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Salivary Gland Disorders and Functions
- Adrenal Hormones and Disorders
Massachusetts General Hospital
2016-2025
Harvard University
2016-2025
Boston University
2005-2024
Radiology Associates
2024
Boston Medical Center
2024
Albany Medical Center Hospital
2023
AstraZeneca (United States)
2023
University of Padua
2023
Hôpital Foch
2023
Great Ormond Street Hospital for Children NHS Foundation Trust
2022
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides J. Jennette;R. Falk;P. Bacon;N. Basu;M. Cid;F. Ferrario;L. Flores-Suarez;W. Gross;L. Guillevin;E. Hagen;G. Hoffman;D. Jayne;C. Kallenberg;P. Lamprecht;C. Langford;R. Luqmani;A. Mahr;E. Matteson;P. Merkel;S. Ozen;C. Pusey;N. Rasmussen;A. Rees;D. Scott;U. Specks;J. Stone;K. Takahashi;R. Watts; Arthritis & Rheumatism
To provide a single source for the best available estimates of US prevalence and number individuals affected by arthritis overall, rheumatoid arthritis, juvenile spondylarthritides, systemic lupus erythematosus, sclerosis, Sjögren's syndrome. A companion article (part II) addresses additional conditions.The National Arthritis Data Workgroup reviewed published analyses from national surveys, such as Health Nutrition Examination Survey Interview (NHIS). For analysis overall we used NHIS....
The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear. We performed a randomized, double-blind, placebo-controlled trial involving confirmed severe acute respiratory syndrome 2 (SARS-CoV-2) infection, hyperinflammatory states, and at least two the following signs: fever (body temperature >38°C), pulmonary infiltrates, or need for supplemental oxygen order to maintain an...
Giant-cell arteritis commonly relapses when glucocorticoids are tapered, and the prolonged use of is associated with side effects. The effect interleukin-6 receptor alpha inhibitor tocilizumab on rates relapse during glucocorticoid tapering was studied in patients giant-cell arteritis.In this 1-year trial, we randomly assigned 251 patients, a 2:1:1:1 ratio, to receive subcutaneous (at dose 162 mg) weekly or every other week, combined 26-week prednisone taper, placebo taper over period either...
John H. Stone, Arezou Khosroshahi, Vikram Deshpande, K. C. Chan, J. Godfrey Heathcote, Rob Aalberse, Atsushi Azumi, Donald B. Bloch, William R. Brugge, Mollie N. Carruthers, Wah Cheuk, Lynn Cornell, Carlos Fernandez-Del Castillo, Judith A. Ferry, David Forcione, Gunter Kloppel, Daniel L. Hamilos, Terumi Kamisawa, Satomi Kasashima, Shigeyuki Kawa, Mitsuhiro Kawano, Yasufumi Masaki, Kenji Notohara, Kazuichi Okazaki, Ji Kon Ryu, Takako Saeki, Dushyant Sahani, Yasuharu Sato, Thomas Smyrk, James...
Objectives To evaluate the efficacy of rituximab (RTX) in IgG4-related disease (IgG4-RD) an open-label pilot trial. Methods We treated 30 IgG4-RD patients with two doses RTX (1000 mg each). The participants were either alone (n = 26; 87%) or required to discontinue baseline glucocorticoids (GC) within 2 months 4; 13%). Disease activity was measured by Responder Index (IgG4-RD RI) and physician's global assessment (PGA). response defined as improvement RI points. primary outcome, at 6 months,...
IgG4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that can affect nearly any organ. Prior studies have focused on individual cases of IgG4-RD or small case series. This study was undertaken to report detailed clinical and laboratory findings in a larger group patients with whose diagnosis established by strict clinicopathologic correlation.The baseline features 125 biopsy-proven were reviewed. The confirmed pathologists' review, based consensus diagnostic...
IgG4-related disease (IgG4-RD) is a novel clinical entity characterized by an elevated serum IgG4 concentration and tumefaction or tissue infiltration IgG4-positive plasma cells. IgG4-RD encompasses wide variety of diseases, formerly diagnosed as Mikulicz's (MD), autoimmune pancreatitis (AIP), hypophysitis, Riedel thyroiditis, tubulointerstitial nephritis, prostatitis, retroperitoneal fibrosis, inflammatory aortic aneurysm pseudotumor. However, like crow flying on dark night, passed through...
Abstract Objective To evaluate treatment with methotrexate (MTX) in patients newly diagnosed giant cell arteritis (GCA) to determine if MTX reduces GCA relapses and cumulative corticosteroid (CS) requirements diminishes disease‐ treatment‐related morbidity. Methods This was a multicenter, randomized, double‐blind study. Over 4 years, 16 centers from the International Network for Study of Systemic Vasculitides enrolled unequivocal GCA. The initial 1 mg/kg/day (≤60 mg every day) prednisone,...
Background: Tumor necrosis factor-α is present in arteries giant cell arteritis. Objective: To evaluate the efficacy of infliximab, an anti–tumor agent, Design: Randomized, controlled trial. Setting: 22 sites United States, Kingdom, Belgium, Italy, and Spain. Patients: 44 patients with newly diagnosed arteritis that was glucocorticosteroid-induced remission. Intervention: Participants were randomly assigned a 2:1 ratio to receive infliximab (5 mg/kg body weight) or placebo. Sixteen...
Patients with IgG4-related systemic disease (IgG4-RSD) frequently show an incomplete response to treatment glucocorticoids and traditional disease-modifying antirheumatic drugs (DMARDs). B lymphocyte depletion is a therapeutic strategy known be effective for pemphigus vulgaris, autoimmune condition mediated by IgG4 autoantibodies. This study was performed assess the clinical serologic responses therapy rituximab in patients IgG4-RSD.Four IgG4-RSD were treated 2 intravenous doses (1 gram...
We evaluated the sensitivity, specificity and positive negative predictive values of elevated serum IgG4 concentrations for diagnosis IgG4-RD.Between 2001 2011, 190 unique patients had measurements. reviewed electronic medical records to determine indication measurement underlying clinical diagnosis. Additionally, we other randomly selected from a pool 3360 with normal results, evaluate test characteristics measurement.Among 380 analysed, 72 either probable or definite IgG4-RD. Sixty-five...
Patients with IgG4-related disease (IgG4-RD) typically have elevated serum concentrations of IgG4 and share histopathologic features that are similar across affected organ(s). IgG4-RD patients frequently require prolonged treatment glucocorticoids often unable to taper these medications. Traditional disease-modifying antirheumatic drugs (DMARDs) generally ineffective. We assessed the clinical serologic responses B lymphocyte depletion therapy in 10 consecutive steroid- DMARD-refractory...
IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic, and pathologic data is required for diagnosis. This work was undertaken to develop validate an international set of classification criteria IgG4-RD.An multispecialty group 86 physicians assembled by the American College Rheumatology (ACR) European League Against Rheumatism (EULAR). Investigators used consensus exercises, existing literature, derivation...
We examined the utility of circulating total and IgG4+ plasmablasts as biomarkers diagnosis disease activity in IgG4-related (IgG4-RD).
Abstract Objective To report baseline data on 180 patients with Wegener's granulomatosis (WG) enrolled in the WG Etanercept Trial (WGET), and to examine demographic clinical differences between limited disease those severe disease. Methods Definitions of were agreed upon by consensus investigators at a pretrial meeting incorporated into protocol as stratification criterion. These applied prospectively WGET patient cohort, based features intention treat according activity. Data related onset,...